(April 17, 2018) Science Translational Medicine recently published a University of Pennsylvania Perelman School of Medicine/University of Lausanne, Switzerland study on using a patient’s immune system to fight their cancer. … Continued
(April 10, 2018) Patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have had at least a partial response to platinum based chemotherapy have a new, FDA … Continued
(April 4, 2018) It’s an exciting time for ovarian cancer research! Ovarian cancer clinicians, researchers and advocates came together in New Orleans at the end of March for the Annual … Continued
(April 3, 2018) A study in the Journal of Clinical Oncology explored the effects of oncologists, rather than genetic counselors, testing ovarian cancer patients for BRCA mutations. Due to the … Continued
(February 22, 2018) Researchers at Roswell Park Comprehensive Cancer Center, including Kunle Odunsi, MD, PhD, senior author of the study and current OCRFA Scientific Advisory Committee member, have discovered a … Continued
(February 14, 2018) Today the US Preventive Task Force updated their recommendation on ovarian cancer screening, reaffirming their 2012 position that screening average risk women for ovarian cancer is not … Continued
(January 31, 2018) A study published in the Annals of Internal Medicine explains that researchers now believe that the methylation of normal BRCA1 gene promotion, not solely BRCA1 mutation, is … Continued
(January 29, 2018) A study recently published in the New England Journal of Medicine looked at the difference between two treatment strategies for newly diagnosed stage III epithelial ovarian cancer … Continued
(January 25, 2018) CancerSEEK is a blood test designed to detect cancer by analyzing levels of proteins and mutations in cell-free DNA. The goal of this particular blood test is … Continued
(January 25, 2018) OCRFA has just awarded more than $5.3 million in new scientific research grants for ovarian cancer, bringing our total investment in life-saving research to over $80 million. … Continued
(December 20, 2017) Cell Reports published new research from the Wistar Institute, which looked at the potential benefits of a therapy that combines PARP inhibitors and BET inhibitors for ovarian … Continued
(December 14, 2017) For over two decades, you have made it possible for OCRFA to fund the most innovative and promising science, resulting in research breakthroughs that have advanced our … Continued
Get email updates about research news, action alerts, and ways to join the fight.
